Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

CeNeS acquires Cambridge NeuroScience for $2.25/share

09 Aug 2000

Executive Summary

In a stock swap, central nervous system therapeutics developer CeNeS Pharmaceuticals PLC will acquire neuroscience drug discovery firm Cambridge NeuroScience paying in CeNes stock $40.8mm or $2.25 for each Cambridge share, representing a (pr)44% premium. Based on the value of CeNeS stock at the agreement's closing, the transaction price could be as high as $44mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By